Biotech company specialized in engineering next-generation biologics to rebalance the immune response in acute and chronic inflammation
Phialogics has raised €600k across 1 funding round from 1 investor, most recently a Pre-Seed round in Apr 2023. Based in Basel, Switzerland; active in Healthtech. Data as of 7 Aug 2026.
Timing: overdue vs cohort gap · momentum unknown. Funding-only estimates, not predictions and not investment advice — see signals.
| Date | Stage | Amount | Investors | |
|---|---|---|---|---|
| 2023-04-19 | Pre-Seed | €600k |
| High-Tech Gründerfonds (HTGF) |
| View deal → |
